Oner P, Gürdöl F, Oner-Iyidon Y, Kolanci C, Büyüköztürk S
Department of Biochemistry, Istanbul Faculty of Medicine, Istanbul University, Capa, 34390, Turkey.
Pharmacol Res. 1999 Aug;40(2):189-93. doi: 10.1006/phrs.1999.0486.
Hypercalcemia and hypercalciuria observed both in humans and in animals who were on long-term theophylline therapy, prompted us to investigate whether oral theophylline treatment at optimal doses causes any adverse side effects on bone metabolism in mild asthmatics. Therefore, serum osteocalcin (BGP) and total alkaline phosphatase (TALP, EC 3.1.3.1) as bone formation markers, serum prolidase I (EC 3.4.13.9) activity as a marker for collagen metabolism, urinary deoxypyridinoline (Dpd), hydroxyproline (Hyp) and fasting urinary calcium as bone resorption markers, were measured in 18 mild asthmatics who had been treated with theophylline over 1-10 years. Among measured bone turnover markers, BGP, TALP, and Hyp levels were found to be increased in mild asthmatics; and BGP showed the greatest percent mean increase (98%) over the healthy subjects. However, these increments did not exceed the upper reference limits. Serum prolidase I activity was also increased in mild asthmatics receiving theophylline. Our results indicate that theophylline therapy at optimal doses may not exert adverse side effects on bone homeostasis, but patients receiving supratherapeutic doses of theophylline should be under close examination in order to predict future bone mass status.
在接受长期茶碱治疗的人类和动物中均观察到高钙血症和高钙尿症，这促使我们研究最佳剂量的口服茶碱治疗是否会对轻度哮喘患者的骨代谢产生任何不良副作用。因此，我们对18名接受茶碱治疗1至10年的轻度哮喘患者进行了检测，测定了作为骨形成标志物的血清骨钙素（BGP）和总碱性磷酸酶（TALP，EC 3.1.3.1）、作为胶原蛋白代谢标志物的血清脯氨酰肽酶I（EC 3.4.13.9）活性、作为骨吸收标志物的尿脱氧吡啶啉（Dpd）、羟脯氨酸（Hyp）以及空腹尿钙。在测定的骨转换标志物中，发现轻度哮喘患者的BGP、TALP和Hyp水平升高；与健康受试者相比，BGP的平均升高百分比最大（98%）。然而，这些升高并未超过参考上限。接受茶碱治疗的轻度哮喘患者的血清脯氨酰肽酶I活性也有所增加。我们的结果表明，最佳剂量的茶碱治疗可能不会对骨稳态产生不良副作用，但接受超治疗剂量茶碱的患者应接受密切检查，以便预测未来的骨量状况。
